Canada Markets closed

BELLUS Health Inc. (BLU.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
5.14+0.44 (+9.36%)
At close: 3:59PM EST
Full screen
Previous Close4.70
Open4.73
Bid5.11 x 0
Ask5.15 x 0
Day's Range4.73 - 5.21
52 Week Range2.70 - 16.68
Volume183,592
Avg. Volume239,846
Market Cap402.654M
Beta (5Y Monthly)-0.37
PE Ratio (TTM)N/A
EPS (TTM)-0.60
Earnings DateFeb. 25, 2021 - Mar. 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.04
  • Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

  • BELLUS Health to Present at the Eleventh International Virtual Cough Symposium
    Business Wire

    BELLUS Health to Present at the Eleventh International Virtual Cough Symposium

    BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Dr. Catherine Bonuccelli, M.D., BELLUS Health's Chief Medical Officer, and Dr. Denis Garceau, Ph.D., Bellus Health’s Senior Vice President of Drug Development, will be presenting data on BLU-5937 at the Eleventh International Virtual Cough Symposium being held on January 21-22, 2021.

  • BELLUS Health Establishes At-the-Market Facility
    Business Wire

    BELLUS Health Establishes At-the-Market Facility

    BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), announces that it has entered today into an agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies") pursuant to which the Company may from time to time in the future sell, through at-the-market distributions with Jefferies acting as sales agent, such common shares as would have an aggregate offer price of up to US$50.0 million, including sales made directly on the Nasdaq Global Market ("Nasdaq") or on any other existing trading market for the common shares in the United States. No common shares will be offered or sold in Canada.